Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I Study of the Anti-C5aR, IPH5401, in Combination With the Anti-PD-L1, Durvalumab, in Patients With Selected Advanced Solid Tumors

Trial Profile

A Phase I Study of the Anti-C5aR, IPH5401, in Combination With the Anti-PD-L1, Durvalumab, in Patients With Selected Advanced Solid Tumors

Recruiting
Phase of Trial: Phase I

Latest Information Update: 15 Nov 2018

At a glance

  • Drugs Durvalumab (Primary) ; IPH 5401 (Primary)
  • Indications Liver cancer; Non-small cell lung cancer; Solid tumours
  • Focus Adverse reactions; Registrational
  • Acronyms STELLAR-001
  • Sponsors Innate Pharma
  • Most Recent Events

    • 15 Nov 2018 According to an Innate Pharma media release, first patient has been dosed in this trial and safety data is expected in 2H 2019.
    • 12 Sep 2018 According to Innate Pharma media release, Innate Pharma and MedImmune (in Jan 2018) entered into a non-exclusive clinical trial collaboration to evaluate the combination of IPH5401 and durvalumab in this study for patients with selected solid tumors. The study is conducted by Innate and the costs are equally shared by both parties.
    • 12 Sep 2018 According to an Innate Pharma media release, the first patient has been enrolled in this study.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top